Cyclacel pharmaceuticals announces exercise of warrants for $2.1 million gross proceeds

Berkeley heights, n.j., nov. 13, 2024 (globe newswire) -- cyclacel pharmaceuticals, inc. (nasdaq: cycc, nasdaq: cyccp; "cyclacel" or the "company"), a biopharmaceutical company developing innovative cancer medicines, today announced that it has entered into a definitive agreement for the exercise of certain existing warrants to purchase an aggregate of 4,968,945 shares of its common stock having an original exercise price of $1.36 per share, originally issued in may 2024, at a reduced exercise price of $0.415 per share. the resale of the shares of common stock issuable upon exercise of the existing warrants is registered pursuant to an effective registration statement on form s-1 (file no. 333-279157).
CYCC Ratings Summary
CYCC Quant Ranking